Autoimmunity reviews Journal Impact Factor & Information

Publisher: Elsevier

Current impact factor: 7.93

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 7.933
2013 Impact Factor 7.095
2012 Impact Factor 7.975
2011 Impact Factor 6.624
2010 Impact Factor 6.556
2009 Impact Factor 6.368
2008 Impact Factor 5.371
2007 Impact Factor 3.862
2006 Impact Factor 3.76
2005 Impact Factor 3.091

Impact factor over time

Impact factor

Additional details

5-year impact 5.96
Cited half-life 3.50
Immediacy index 2.98
Eigenfactor 0.02
Article influence 1.40
ISSN 1873-0183

Publisher details


  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Authors pre-print on any website, including arXiv and RePEC
    • Author's post-print on author's personal website immediately
    • Author's post-print on open access repository after an embargo period of between 12 months and 48 months
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months
    • Author's post-print may be used to update arXiv and RepEC
    • Publisher's version/PDF cannot be used
    • Must link to publisher version with DOI
    • Author's post-print must be released with a Creative Commons Attribution Non-Commercial No Derivatives License
    • Publisher last reviewed on 03/06/2015
  • Classification

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Extracellular vesicles (EVs) consist of exosomes released upon fusion of multivesicular bodies with the cell plasma membrane and microparticles shed directly from the cell membrane of many cell types. EVs can mediate cell-cell communication and are involved in many processes including inflammation, immune signalling, angiogenesis, stress response, senescence, proliferation, and cell differentiation. Accumulating evidence reveals that EVs act in the establishment, maintenance and modulation of autoimmune processes among several others involved in cancer and cardiovascular complications. EVs could also present biomedical applications, as disease biomarkers and therapeutic targets or agents for drug delivery.
    Autoimmunity reviews 11/2015; DOI:10.1016/j.autrev.2015.11.004
  • [Show abstract] [Hide abstract]
    ABSTRACT: Spondyloarthritis (SpA) and inflammatory bowel disease (IBD) are chronic autoinflammatory diseases that partially share the genetic predisposition and the unchecked inflammatory response linking the gut to the joints. The coexistence of both conditions in patients and the increased cross-risk ratios between SpA and IBD strongly suggest a shared pathophysiology. The prevalence of Enteropathic-related Spondyloarthritis (ESpA) in IBD patients shows a wide variation and may be underestimated. It is well accepted that the management of joint pain requires rheumatological expertise in conjunction with gastroenterologist assessment. In this view, we aimed at assessing, in a prospective study performed in a combined Gastro-Intestinal and Rheumatologic "GI-Rhe" clinic: (1) the prevalence of ESpA and other rheumatologic diseases in IBD patients with joint pain; (2) the features of the ESpA population; (3) the diagnostic delay and the potential impact of the combined assessment. From November 2012 to December 2014, IBD patients with joint pain referring to a dedicated rheumatologist by the IBD-dedicated gastroenterologist were enrolled. Clinical and biochemical evaluations, joint involvement and disease activity assessment, diagnostic delay, and treatment were recorded. IBD patients (n=269) with joint pain were jointly assessed in the "GI-Rhe" Unit. A diagnosis of ESpA was made in 50.5% of IBD patients with joint pain. ESpA patients showed a peripheral involvement in 53% of cases, axial in 20.6% and peripheral and axial in 26.4% of cases. ESpA patients had a higher prevalence of other autoimmune extra-intestinal manifestations and received more anti-TNF treatment compared with IBD patients. A mean diagnostic delay of 5.2 years was revealed in ESpA patients. Patients with joint disease onset in the 2002-2012 decade had reduced diagnostic delay compared with those with onset in the 1980-1990 and 1991-2001. Diagnostic delay was further reduced for patients with joint onset in the last two years in conjunction with the establishment of the GI-Rhe clinic. Multidisciplinary approach improved management of rheumatic disorders in IBD patients allowing a more comprehensive care.
    Autoimmunity reviews 11/2015; DOI:10.1016/j.autrev.2015.11.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: We aim to review the literature on APD and evaluate the different theories of pathogenesis and treatments for this condition. Methods: A review of the English literature on APD was performed using PubMed, EMBASE and MEDLINE. Results: 89 patients are included in this review. Initial symptom development in association with the menstrual cycle was reported in 65 (73%) patients. In some patients, it occurred shortly after hormone therapy (8.9%) or in relation to a pregnancy (14.6%). Associated factors were not defined in three patients (3.4%). Nearly 45% had a history of exposure to exogenous progesterone. Diagnosis of APD was usually confirmed with an intradermal progesterone sensitivity test. The goal of treatment was to suppress progesterone secretion through anovulation. Some cases were controlled with oral contraceptives or conjugated estrogen, while some patients had complete resolution post-hysterectomy. Conclusion: The wide spectrum of clinical presentations, histology, and response to therapy would suggest that there are multiple subsets in APD. The increase in the levels of progesterone may also influence the clinical profile and the corresponding immunological response. Further research on the pathogenesis of APD is required to provide a satisfactory treatment modality.
    Autoimmunity reviews 11/2015; DOI:10.1016/j.autrev.2015.11.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: The vasculitides form a heterogeneous group of systemic diseases that differ in etiology, histological patterns, and, consequently, clinical significance and prognosis, but are traceable to the same pathological event, namely vessel wall inflammation. The clinical heterogeneity among these diseases, together with yet unknown pathogenetic mechanisms for many of them, creates difficulties in the early diagnosis and correct management of affected patients. Therefore, several groups of investigators have elaborated nomenclatures to set some order in the definition and grouping of the vasculitides. The two main naming systems used for decades, i.e. the Fauci nomenclature and the 1994 Chapel Hill Consensus Conference (CHCC) nomenclature, were recently superseded by a revised CHCC nomenclature published in 2012. The aim of that revision was to update the names and definitions of the vasculitides and to include novel forms, considering the advances in knowledge made since the first consensus conference was held. Here, we critically discuss the 2012 CHCC nomenclature in light of the earlier naming systems and raise some concerns in how several vasculitides were grouped. On the basis of this analysis, we propose an integrated nomenclature that we believe will have a more direct impact in the clinic, perfectly aware that any redefinition may present contradictions.
    Autoimmunity reviews 11/2015; DOI:10.1016/j.autrev.2015.10.008
  • [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to determine the prevalence and predictive validity of serum ANA and -ENA for connective tissue diseases (CTD), cancer, and mortality. We took advantage of a 1998 population (Isola I) of 2828 subjects (1510/2828 women, age 43±13 years) of a well-defined Northern Italian area and performed serum ANA and anti-ENA testing on 2690 samples available in 2012 (Isola II, 1336/2690 women, age 58±13 years). Administrative databases were analyzed for CTD and cancer diagnosis, and death cases occurring between enrollment and December 31, 2013. The 15-year relative risk and hazard ratio (HR) were calculated for CTD, cancer, and death cases. Serum ANA were positive in 18.1% for any titer and 6.1% for titers ≥1:160, 23% in subjects over 50 years and 13.1% and 6.1% for any titer and titers ≥1:160, respectively, in women. The HR for CTD development over 15 years was significantly higher for all ANA titers, with the highest for ANA ≥1:160 (HR 14.19, 95% CI 3.07-65.68). ANA positivity was not associated with cancer onset (HR 1.03; 95% CI 0.75-1.43), and with mortality (HR adjusted for age and sex 1.40; 95% CI 0.94-2.09). Serum anti-ENA were positive in a minority of subjects with highest figures for anti-nucleosome (1.9%), -histone (1.6%) and -PM/Scl (1.5%). ANA prevalence in the general population is higher than expected, but the female predominance is significantly lower compared to the overt CTD. Serum ANA is associated with a significant HR for CTD development over time, but does not change survival or cancer risk.
    Autoimmunity reviews 11/2015; DOI:10.1016/j.autrev.2015.10.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anti-DFS70 antibodies and their clinical associations remain an immunological paradox. Unlike other antinuclear antibodies (ANA), especially when present at high titres, anti-DFS70 antibodies are not prevalent in ANA associated rheumatic diseases. Despite significant interest and progress in understanding the clinical association of anti-DFS70 antibodies, no restrict clinical association has been confirmed. In reality, several studies reporting clinical association of these antibodies (i.e. atopic dermatitis, thrombosis, autoimmune thyroiditis) have added confusion instead of bringing significant insight. In addition, several groups have consistently reported on the occurrence of anti-DFS70 antibodies in a relevant fraction of apparently healthy individuals. This review aims to analyse the current knowledge and to provide future guidance to analyse potential clinical associations of anti-DFS70 antibodies by summarizing and interpreting recent findings.
    Autoimmunity reviews 11/2015; DOI:10.1016/j.autrev.2015.11.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple sclerosis (MS) is an immune mediated disease of the central nervous system (CNS) and the leading cause of non-traumatic disability among young and middle-aged adults in the western world. One of its most prevalent and debilitating symptoms is fatigue. Despite the general acceptance of the idea of an immune pathogenesis of MS itself, the role of autoimmunity in the course of MS-fatigue is a matter of debate. Both immune-related processes (acute inflammation, chronic inflammation, immune-mediated neurodegeneration, immune-mediated alterations of endocrine functions related to fatigue) and presumably non-immune-mediated disturbances and factors (sleep disturbances, depression, cognitive alterations, chronic infections, adverse effects of medications) contribute to the clinical picture. Data from in vitro and animal experiments has provided evidence for a role of cytokines as IL-1 and TNF-alpha. This association could not be verified directly in blood samples from humans whereas whole blood stimulation protocols gave some indirect evidence for a role of cytokines in MS-fatigue. MRI being able to detect acute and chronic immune mediated damage to the CNS could depict that global atrophy of grey or white matter does not correlate with fatigue. Rather, distinctive clusters of lesions and atrophy at different locations, mostly bifrontal or in subcortical structures, correlate specifically with fatigue. Regardless of the difficulties in pinpointing the immunogenesis of MS-fatigue, an important role of autoimmunity is strongly supported by an indirect route: A growing amount of data shows that the highly effective immunotherapeutics which have been introduced to MS-treatment over the last years effectively and sustainably stabilize and ameliorate fatigue in parallel to their dampening effects on the neuroinflammatory process. This review summarizes the existing data on the relation between inflammation, patterns of CNS-lesions and the effects of immunotherapeutics on MS-fatigue.
    Autoimmunity reviews 11/2015; DOI:10.1016/j.autrev.2015.11.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Systemic Lupus Erythematosus (SLE) is associated with increased risk of cardiovascular disease. Carotid intima media thickness (CIMT) and carotid plaques are both frequently used to identify populations at higher cardiovascular risk. A systematic literature search and meta-analysis were performed to evaluate CIMT and carotid plaques difference between SLE patients and normal controls. Methods: The literatures comparing markers of cardiovascular risk (CIMT and prevalence of carotid plaques) in SLE and controls were systematically searched in PubMed, EMBASE and Cochrane databases. The overall mean CIMT difference and pooled odds ratio (OR) for the prevalence of carotid plaques between SLE patients and control groups were calculated by fixed-effects or random-effect model analysis. Meta-regression was performed to explore the potential influencing factors. Publication bias was examined by a funnel plot and Egger's test. Results: A total of 80 studies (6085 SLE patients and 4794 controls) were included in the final analysis, 71 studies with data on CIMT (4814 cases and 3773 controls) and 44 studies reporting on the prevalence of carotid plaques (4417 cases and 3528 controls). As compared to controls, SLE patients showed a higher CIMT (WMD: 0.07 mm; 95 %CI: 0.06, 0.09; P < 0.001), and an increased prevalence of carotid plaques (OR: 2.45; 95 %CI: 2.02, 2.97; P < 0.001). Meta-regression models showed that traditional cardiovascular risk factors (age, HDL and triglyceride of SLE patients) and lupus related risk factors (as expressed by duration, ESR, SLEDAI and steroids) had significant influence on CIMT, steroids and triglyceride had significant influence on the prevalence of carotid plaques. Conclusions: Our findings support the current evidence base for an increased cardiovascular burden in SLE patients and support the use of CIMT and carotid plaques in observational studies in SLE patients. The findings are of importance to design more specific prevention and treatment strategies.
    Autoimmunity reviews 10/2015; DOI:10.1016/j.autrev.2015.10.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Eosinophilic granulomatosis with polyangitis (EGPA) is a rare small- and medium-sized vessel vasculitis belonging to the group of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV). It is commonly divided into two phenotypes depending on the presence of ANCAs targeting myeloperoxidase (MPO). MPO-ANCAs are present in 31% to 38% of patients and are associated with a vasculitis phenotype of the disease, whereas patients without MPO-ANCA are at risk of cardiac involvement. Despite significant advances in understanding the overall pathogenesis of the disease, the explanation for this dichotomy is still unclear. In this review, we synthesize our knowledge of the pathogenesis of EGPA and attempt to i) distinguish EGPA from other diseases including other AAVs, asthma, allergy and hypereosinophilic-associated conditions and ii) speculate about the preponderant mechanisms, which could explain the two disease phenotypes.
    Autoimmunity reviews 10/2015; DOI:10.1016/j.autrev.2015.10.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: To describe the clinical features, treatment and outcome of autoimmune diseases (AD) in a cohort of patients with thymoma. Design: Pathological records from three university hospitals, between 2005 and 2011 were reviewed to identify patients with thymoma. Patients with thymoma and AD were compared with patients with thymoma without AD. Results: 47/85 (55%) cases of thymoma had AD including: myasthenia gravis (MG) (n=33), Hashimoto's thyroiditis (n=4), Isaac's syndrome (n=3), Morvan syndrome (n=2), pure red cell aplasia (n=2), systemic lupus (n=2), lichen planus (n=2), and one case of each following conditions: aplastic anemia, autoimmune hemolytic anemia, Good's syndrome, pemphigus, autoimmune hepatitis, Graves' disease, limbic encephalitis and inflammatory myopathy. Six patients (7%) presented at least 2 ADs. The median duration of follow-up after surgery was 60 months (40-78 months). In 32 patients the diagnosis of AD preceded the diagnosis of thymoma, in 9 patients, thymoma was diagnosed at the same time as the AD and 7 patients had been operated when they developed an AD. We found a significative difference on the Masaoka stage between the MG patients and the patients who present another AD (p=0.028). No risk factor for developping an AD after thymectomy was identified. Conclusions: We describe here the long-term follow-up of a large series of AD related to thymoma. Our results confirm previous data concerning AD occurrence in patients with thymoma and suggest that preexisting autoimmunity is not a risk factor for developping autoimmune manifestations after thymectomy.
    Autoimmunity reviews 09/2015; DOI:10.1016/j.autrev.2015.09.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunoglobulin (IG) therapy is actually used for a broad range of diseases including primary and secondary immunodeficiency disorders, and autoimmune diseases. This therapy is available for intravenous (IV) and subcutaneous (SC) administration. The efficacy of the IG therapy has been demonstrated in numerous studies and across different diseases. Generally, IG infusions are well tolerated; however some well-known adverse reactions, ranging from mild to severe, are associated with the therapy. The most common adverse reactions including headache, nausea, myalgia, fever, chills, chest discomfort, skin and anaphylactic reactions, could arise immediately during or after the infusion. Delayed events could be more severe and include migraine headaches, aseptic meningitis, haemolysis renal impairment and thrombotic events. This paper reviews all the potential adverse events related to the IG therapy and establishes a comprehensive guideline for the management of these events. Moreover it resumes the opinions and clinical experience of expert endorsers on the utilisation of the treatment. Published data were classified into levels of evidence and the strength of the recommendation was given for each intervention according to the GRADE system.
    Autoimmunity reviews 09/2015; DOI:10.1016/j.autrev.2015.09.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is growing interest in the role of tacrolimus as a potential therapeutic agent in SLE. This systematic review and meta-analysis evaluates the evidence for tacrolimus use in the management of lupus nephritis. Thirteen controlled studies were identified (9 suitable for inclusion), using Cochrane database, SCOPUS, Web of Science and OVID (MEDLINE and EMBASE). Data on complete and partial remission rates, proteinuria reduction and adverse events was extracted and analysed using RevMan software. The meta-analysis showed that overall tacrolimus is more effective at inducing complete renal remission than IVCYC (p=0.004), but there is no significant difference compared to MMF (p=0.87). Multi-target TAC+MMF therapy is more effective than IVCYC only when partial remission is included (p=0.0006). Frequency of key adverse effects seems comparable to other agents used in the management of lupus nephritis with fewer gastrointestinal side effects, leukopenia, menstrual disorders, infections and episodes of liver dysfunction reported, but more new onset hypertension and hyperglycaemia. Mortality was lower in the tacrolimus groups, but this was not statistically significant (p=0.15). Tacrolimus may be more effective at reducing proteinuria, but again this was not statistically significant. There are no controlled trials looking use in pregnancy or juvenile patients, however case reports suggest potential efficacy and safety. In conclusion, in moderately severe lupus nephritis, there is some evidence supporting efficacy of tacrolimus or multi-target TAC+MMF over IVCYC, but no evidence supporting tacrolimus over MMF. Tacrolimus may be more effective at reducing proteinuria, having potential implications for long-term outcome. Key limitations of this study are the lack of long-term outcome data and the lack of high quality, large, blinded controlled trials in multi-ethnic groups.
    Autoimmunity reviews 09/2015; DOI:10.1016/j.autrev.2015.09.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: The antiphospholipid syndrome (APS) is a systemic autoimmune disease that is characterized serologically by the presence of antiphospholipid antibodies (aPL) and clinically by vascular thrombosis and obstetric complications. The protein β2 glycoprotein I (β2GPI) is identified as the most important autoantigen in this syndrome. Activation of endothelial cells, thrombocytes and placental tissue by anti-β2GPI antibodies relates to the clinical manifestations of APS. This review describes genetic and environmental factors in relation to APS and summarizes current knowledge on abnormalities in components of both the innate and adaptive immune system in APS. The role of dendritic cells, T-cells, B-cells, monocytes, neutrophils and NK-cells as well as the complement system in APS are discussed. Several gaps in our knowledge on the pathophysiology of APS are identified and a plea is made for future extensive immune cell profiling in order to better unravel the pathogenesis of APS, to gain more insight in the role of the immune system in APS as well as having the potential to reveal biomarkers or novel therapeutic targets. Copyright © 2015. Published by Elsevier B.V.
    Autoimmunity reviews 08/2015; DOI:10.1016/j.autrev.2015.08.011
  • [Show abstract] [Hide abstract]
    ABSTRACT: Toll-like receptors (TLRs) constitute an important mechanism in the activation of innate immune cells including monocytes, macrophages and dendritic cells. Macrophage activation by TLRs is pivotal in the initiation of the rapid expression of pro-inflammatory cytokines TNF, IL-1β and IL-6 while promoting Th17 responses, all of which play critical roles in autoimmunity. Surprisingly, in inflammatory arthritis, activation of specific TLRs can not only induce but also inhibit cellular processes associated with bone destruction. The intercellular and intracellular orchestration of signals from different TLRs, their endogenous or microbial ligands and accessory molecules determine the activating or inhibitory responses. Herein, we review the TLR-mediated activation of innate immune cells in their activation and differentiation to osteoclasts and the capacity of these signals to contribute to bone destruction in arthritis. Detailed understanding of the opposing mechanisms of TLRs in the induction and suppression of cellular processes in arthritis may pave the way to develop novel therapies to treat autoimmunity. Copyright © 2015. Published by Elsevier B.V.
    Autoimmunity reviews 08/2015; DOI:10.1016/j.autrev.2015.08.009